8/7/2019 Presentation - Lab on a Chip - Dale Athey
1/28
Lab on a chip how microdiagnostics
are revolutionising healthcare
NETPark Incubator 1st
June 2009
Dale Athey
CEO, Orla Protein Technologies Ltd
8/7/2019 Presentation - Lab on a Chip - Dale Athey
2/28
There are several major global drivers
forin vitro and molecular diagnostics
Increase in
Chronic Disease
Availability ofhigh
value diagnostics
Growth indecentralised
healthcare
An aging population
8/7/2019 Presentation - Lab on a Chip - Dale Athey
3/28
How can we successfully capture some
of the commercial opportunity ?
8/7/2019 Presentation - Lab on a Chip - Dale Athey
4/28
Whilst attractive the market is highly
competitive
8/7/2019 Presentation - Lab on a Chip - Dale Athey
5/28
We can learn from the experience of
others
8/7/2019 Presentation - Lab on a Chip - Dale Athey
6/28
I would like to share my experience with
Orla Protein Technologies
1.
Orla background
2.
Diagnostics
3.
Commercialisationissues
8/7/2019 Presentation - Lab on a Chip - Dale Athey
7/28
1.Orla background
8/7/2019 Presentation - Lab on a Chip - Dale Athey
8/28
Orla is a spinout from Newcastle University
1. Orla background
8/7/2019 Presentation - Lab on a Chip - Dale Athey
9/28
Opportunity
the highest growth rates will
be in the convergence
between bio- and nano-technologies in the
healthcare and
pharmaceutical sectors
1. Orla background
Source Cientifica Ltd: Nanotechnology
Opportunity Report, 3rd Edition. June
2008
8/7/2019 Presentation - Lab on a Chip - Dale Athey
10/28
Orla design, and manufacture proteins for
surface applications
5nm
gene bacteria purified proteinsurface
1. Orla background
8/7/2019 Presentation - Lab on a Chip - Dale Athey
11/28
The platform has wide application
1. Orla background
8/7/2019 Presentation - Lab on a Chip - Dale Athey
12/28
1. Orla background
Convergence ofelectronics and biotechnology
8/7/2019 Presentation - Lab on a Chip - Dale Athey
13/28
2.Diagnostics
8/7/2019 Presentation - Lab on a Chip - Dale Athey
14/28
2. Diagnostics
Partnership with Japan Radio Company
8/7/2019 Presentation - Lab on a Chip - Dale Athey
15/28
4 Millionpieces permonth
2. Diagnostics
Manufacturing capability
8/7/2019 Presentation - Lab on a Chip - Dale Athey
16/28
LAN
PHS
ETC ETC
W-CDMA
SAW
GPS
GPS IP
SSLPHS
26GHz P-MPIP
*+]):$
*+]0ESV
VICS
2. Diagnostics
Communications expertise
8/7/2019 Presentation - Lab on a Chip - Dale Athey
17/28
SAW
2. Diagnostics
Joint venture on a next generation
diagnostics platform
8/7/2019 Presentation - Lab on a Chip - Dale Athey
18/28
2. Diagnostics
Prototypes already available
8/7/2019 Presentation - Lab on a Chip - Dale Athey
19/28
2. Diagnostics
Other benefits of technology
8/7/2019 Presentation - Lab on a Chip - Dale Athey
20/28
Technology Strategy Board Funding
New rapid testing device will target respiratory disease24 October 2008
Newcastle-Upon-Tyne UK. Newcastle-based nano-
biotechnology firm Orla Protein Technologies Ltd,
has secured a government investment of nearly
700,000 to help its wireless electronic technology
for the rapid detection of respiratory viruses such
as Respiratory Syncitial Virus (RSV) and Influenza
(Flu).
The 1.1M development project VIRASENS, is
part-funded by a collaborative R&D grant from theTechnology Strategy Board
2.Diagnostics
8/7/2019 Presentation - Lab on a Chip - Dale Athey
21/28
3.
Commercialisation
issues
8/7/2019 Presentation - Lab on a Chip - Dale Athey
22/28
Micro diagnostics and miniaturisation
have a role
3. Commercialisation issues
8/7/2019 Presentation - Lab on a Chip - Dale Athey
23/28
Its a long journey from the University
bench tocommercial success
3. Commercialisation issues
8/7/2019 Presentation - Lab on a Chip - Dale Athey
24/28
Universities
Degree ofCommercial Opportunity
Commercial risk
Commercial interest
Science Technology Business
3. Commercialisation issues
8/7/2019 Presentation - Lab on a Chip - Dale Athey
25/28
Technology is only a small part of
commercialisation
Technology Risk does it work ?
Data Risk does it work in application area ?
Product Risk can you manufacture ?
Commercialisation Risk reimbursement, regulatory
3. Commercialisation issues
8/7/2019 Presentation - Lab on a Chip - Dale Athey
26/28
To bring a new biomarker-based
diagnostic test to market takes
an estimated 3 years and $45-
50Mto complete outcome
studies. From first investment to
revenues this estimate rises to
$70-100M
3. Commercialisation issues
Howwill you finance the development ?
VC panel comment at CHI Molecular medicine
Triconference in San Fransisco, 2009
8/7/2019 Presentation - Lab on a Chip - Dale Athey
27/28
We can successfully capture some of
the commercial opportunity ?
need to think about
business model not just
technology
Yes..but
8/7/2019 Presentation - Lab on a Chip - Dale Athey
28/28
Thank you for your attention
www.orlaproteins.com